Observational study of newer immunotherapies for multiple myeloma in Norway
Studies how well and how safely newer immunotherapies work in routine care for myeloma.
Plain-language title generated from the registry record
Registry title: The Norwegian Immunotherapy in Multiple Myeloma Study
Key facts
- Where
- Ålesund, Arendal, Bærum, Bergen, Bodø, Drammen, Førde, Gjøvik, Haugesund, Kristiansand, Kristiansund, Levanger, Molde, Nordbyhagen, Oslo, Skien, Stavanger, Tønsberg, Tromsø, Trondheim, and Volda, NorwaySee the 23 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for adults with multiple myeloma, primary plasma cell leukemia or AL-amyloidosis who are planned to get one of five newer immunotherapy drugs in routine care in Norway.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- A diagnosis of multiple myeloma, primary plasma cell leukemia or AL-amyloidosis, as defined by IMWG criteria
- Earlier treatment
- Planned treatment with teclistamab (Tecvayli), elranatamab (Elrexfio), talquetamab (Talvey), idecabtagene vicleucel (ide-cel/Abecma) or ciltacabtagene autoleucel (cilta-cel/Carvykti), given outside a clinical trial
Read by machine on 12 November 2026.
Where in Norway
- Ålesund hospital, Department of hematologyÅlesund, NorwayContact: Eivind Samstad, MD PhDNot yet recruiting
- Sørlandet hospital ArendalArendal, NorwayContact: Silje Beate Holck-Steen, MDNot yet recruiting
- Bærum HospitalBærum, NorwayContact: Hanne Kristin Fredly, MDNot yet recruiting
- Haukeland University HospitalBergen, NorwayContact: Galina Tsykunova, MDNot yet recruiting
- Bodø HospitalBodø, NorwayContact: Terje Solhaug, MDNot yet recruiting
- Drammen hospitalDrammen, NorwayContact: Anne Elisabeth Tónay, MDNot yet recruiting
- Førde HospitalFørde, NorwayContact: Damian Szatkowski, MDNot yet recruiting
- Innlandet hospital trustGjøvik, NorwayContact: Kristoffer Winje, MDNot yet recruiting
- Haugesund HospitalHaugesund, NorwayContact: Camilla S Bjørnsen, MD PhDNot yet recruiting
- Sørlandet hospitalKristiansand, NorwayContact: Hedda Lerdal, MDNot yet recruiting
- Nordmøre and Romsdal Hospital - KristiansundKristiansund, NorwayContact: Tarjei S Rønning, MDNot yet recruiting
- Levanger HospitalLevanger, NorwayContact: Vidar Stavseth, MDNot yet recruiting
- Nordmøre and Romsdal Hospital - MoldeMolde, NorwayContact: Per Arne Standal, MDNot yet recruiting
- Akershus University Hospital (AHUS)Nordbyhagen, NorwayContact: Anette L Eilertsen, MD PhDNot yet recruiting
- Diakonhjemmet HospitalOslo, NorwayContact: Erik Ø Bjørnestad, MDNot yet recruiting
- Lovisenberg Diaconal HospitalOslo, NorwayContact: Astrid Bergrem, MD PhDNot yet recruiting
- Oslo Myeloma Center, Oslo University HospitalOslo, NorwayContact: Ingerid W Abrahamsen, MD PhDNot yet recruiting
- Telemark Hospital TrustSkien, NorwayContact: Lloyd Frode Ramslien, MDNot yet recruiting
- Stavanger University HospitalStavanger, NorwayContact: Kari Lenita F Moore, MDNot yet recruiting
- Vestfold Hospital TrustTønsberg, NorwayContact: Magnus Moksnes, MDNot yet recruiting
- University Hospital of North NorwayTromsø, NorwayContact: Gøril Heide, MD PhDNot yet recruiting
- St. Olavs hospital HFTrondheim, NorwayContact: Tobias S Slørdahl, MD PhDTaking people
- Volda hospitalVolda, NorwayContact: Elin O Velle, MDNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- St. Olavs Hospital
- Trial code
- NCT06855121
- Record updated
- 20 July 2026
- Original description
The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.Read full original descriptionShow less
The Norwegian Immunotherapy in Multiple Myeloma Study - A Population-based Longitudinal Observational Multicenter Study on Effectiveness and Complications of Immunotherapy in Multiple Myeloma in the Norwegian Myeloma Cohort
The goal of this observational study is to study the effectiveness and complications of novel immunotherapies used in the treatment of multiple myeloma in routine care in Norway. The aim is to close knowledge gaps, generate evidence for future clinical trials and contribute to future consensus on how to monitor for adverse events, and what mitigation strategies should be implemented, so that we can increase patient survival and quality-of-life.
Inclusion: Participants age ≥ 18 years; Prior diagnosis of one of the following; Multiple myeloma as defined according to IMWG criteria; Primary plasma cell leukemia as defined according to IMWG consensus definition; AL-amyloidosis as defined according to IMWG criteria; Planned treatment with one of the following outside clinical trials (list to be amended based on approvals within the EU):; Teclistamab (Tecvayli); Elranatamab (Elrexfio); Talquetamab (Talvey); Idecabtagene vicleucel (ide-cel/Abecma); Ciltacabtagene autoleucel (cilta-cel/Carvykti).
Exclusion: None.